Purinergic Signalling (2008) 4:85–87
DOI 10.1007/s11302-007-9092-9

ERRATUM

P2 receptors in cardiovascular regulation and disease

David Erlinge · Geoffrey Burnstock

Published online: 22 January 2008

Erratum to: Purinergic Signalling
DOI 10.1007/s11302-007-9078-7

In Table 1, at line 8 after $P2Y_{14}$: "IP3" should be changed to "↓cAMP".

In Fig. 2, lower left in the VSMC: $P2Y_{12}$ should be $P2Y_2$.

The online version of the original article can be found at:
http://dx.doi.org/10.1007/s11302-007-9078-7.

D. Erlinge
Department of Cardiology, Lund University Hospital,
22185 Lund, Sweden
e-mail: david.erlinge@med.lu.se

G. Burnstock (✉)
Autonomic Neuroscience Centre,
Royal Freee and University College Medical School,
Rowland Hill Street,
London NW3 2PF, UK
e-mail: g.burnstock@ucl.ac.uk

Table 1 Receptor classification, intracellular signalling, ligands and selective agonists and antagonists

P2 subtype	I.c. signalling	Ligand	Selective agonist	Selective antagonist	Non-selective antagonist
$P2Y_1$	↑IP3	ADP (ATP)	MRS2365	MRS 2179, MRS2500	
$P2Y_2$	↑IP3	UTP = ATP	MRS2498, UTPγS, INS3717		Suramin > RB2
$P2Y_4$	↑IP3	UTP (=ATP In rodents)	UTPγS, INS3717	–	RB2 > Suramin
$P2Y_6$	↑IP3	UDP	MRS2666, MRS2633, UDPβS	MRS2578	
$P2Y_{11}$	↑IP3, ↑cAMP	ATP	AR-C67085MX, NF546	NF157	Suramin > RB2
$P2Y_{12}$	↓cAMP	ADP	–	Clopidogrel, prasugrel, AZD6140, INS50589, AR-C9931 (cangrelor)	
$P2Y_{13}$	↓cAMP	ADP	–	MRS2211	
$P2Y_{14}$	↓cAMP	UDP-glucose, UDP-galactose	UDP-glucose, UDP-galactose	–	
$P2X_1$	Positive ion channel	ATP	α,β-mATP	NF023, NF449	TNP-ATP, Ip_5I
$P2X_2$	Positive ion channel	ATP	–	NF770	Suramin, isoPPADS, RB2
$P2X_3$	Positive ion channel	ATP	α,β-mATP	A317491, NF110	Suramin
$P2X_4$	Positive ion channel	ATP	Ivermectin potentiates	–	TNP-ATP
$P2X_5$	Positive ion channel	ATP	–	–	Suramin, PPADS
$P2X_6$	Positive ion channel	ATP	–	–	–
$P2X_7$	Positive ion channel	ATP	–	KN62, KN04, MRS2427	Coomassie brilliant blue G
Ectonucleotidase			Apyrase, human SolCD39	ARC67156	



Fig. 2 Functional roles of P2 receptors in the atherosclerotic inflammatory plaque and during restenosis. See text for details. Purines and pyrimidines acting on P2 receptors stimulate vascular inflammation both by actions on the endothelial cell (*EC*) and by effects on inflammatory cells. Furthermore, they stimulate vascular smooth muscle cell (*VSCM*) proliferation, the conversion to synthetic phenotype and production of matrix proteins. Mitogenic P2 receptors are upregulated by growth factors and cytokines. *IL* interleukin, *MCP-1* monocyte chemoattractant protein-1, *ICAM-1* intercellular adhesion molecule-1, *TSP* thrombospondin, *IDO* indoleamine 2,3-dioxygenase